- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
July 16, 2024David Martinez Named To 2024 Leaders of Influence: Litigators & Trial Attorneys by Los Angeles Business Journal
-
July 16, 2024Robins Kaplan Ranked Among Best Law Firms for Training and Professional Development
-
July 15, 2024IAM Patent 1000 Recommends Robins Kaplan, Nine Partners for Patent Litigation
-
July 18, 2024Trial Skills: Examination of Expert Witnesses - Direct and Cross
-
August 6, 2024Identifying Opportunities: Affirmative Recovery Strategies
-
October 21, 2024How Much Did We Invest in AI?
-
Second QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
July 12, 2024Litigation Perspective: Strategies for Licensing Software that Leverages Artificial Intelligence
-
June/July 2024A Dive Into Intellectual Property Liability For E-Commerce Platforms
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Abbreviated New Drug Applications and 505(b)(2) Applications
Second Quarter
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
| Reference Listed Drug | ANDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
|---|---|---|---|---|---|
| Oracea | Galderma | doxycycline | Lupin | Used for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. | 4/9/2024 |
| Fleqsuvy | Azurity | baclofen | ANI | Used for the treatment of pain and certain types of spasticity (muscle stiffness and tightness) from multiple sclerosis, spinal cord injuries, or other spinal cord diseases. | 4/9/2024 |
| Toviaz | Hetero | fesoterodine fumerate | Camber | Used for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. | 4/17/2024 |
| Myrbetriq ER | Astellas | mirabegron | Lupin | Used for the treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. | 4/20/2024 |
| Myrbetriq ER | Astellas | mirabegron | Zydus | Used for the treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. | 4/22/2024 |
| EstroGel | Ascend | estradiol | Solaris | Used for the treatment of moderate to severe vasomotor symptoms due to menopause, and for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. | 4/25/2024 |
| Abilify OS | Bristol-Myers Squibb | aripiprazole | Camber | Used for the treatment of schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s Disorder | 4/26/2024 |
| Cupric Chloride | Hospira | cupric chloride | Somerset Therapeutics | Used as a supplement to intravenous solutions given for TPN. Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. | 5/1/2024 |
| Viibryd | AbbVie | vilazodone | Apotex | Used for the treatment of major depressive disorder (MDD). | 5/2/2024 |
| Oracea | Galderma | doxycycline | Dr. Reddy's Labs | Used for the treatment of bacterial infections, including acne, rosacea, urinary and respiratory tract infections, eye infections, gum disease, gonorrhea, chlamydia, and syphilis. Doxycycline can also be used to prevent malaria and treat infections caused by mites, ticks, or lice. | 5/3/2024 |
| Cialis | Eli Lilly | tadalafil | TWi | Used for the treatment of erectile dysfunction (ED, impotence; inability to get or keep an erection), and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate) which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying), painful urination, and urinary frequency and urgency in adult men. | 5/6/2024 |
| Halaven | Eisai | eribulin | Apotex | Used for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. | 5/7/2024 |
| Esbriet | Genentech | pirfenidone | Apotex | Used for the treatment of idiopathic pulmonary fibrosis (IPF). | 5/8/2024 |
| Cetrotide | Merck | cetrorelix | Apotex | Used for the prevention of premature ovulation in women undergoing controlled ovarian stimulation therapy followed by oocyte retrieval and assisted reproductive technology. | 5/14/2024 |
| Narcan | Emergent | naloxone | Walgreens | Used for the reversal of an opioid overdose or suspected opioid overdose: it is intended for immediate administration as emergency therapy in settings where opioids may be present | 5/15/2024 |
| Banzel | Eisai | rufinamide | Camber | Used for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults. | 5/16/2024 |
| Norepinephrine Bitartrate | Long Grove | norepinephrine bitartrate | Long Grove | Used for to raise blood pressure in adult patients with severe, acute hypotension, and it is one of the most commonly used injectable medications in the critical care setting. | 5/22/2024 |
| Vibramycin | Pfizer | doxycycline | Lupin | Used for to reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline and other antibacterial drugs. | 6/3/2024 |
| Sodium Acetate | Hospira | sodium acetate | Hikma | Used for as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. | 7/11/2024 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
Second Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
June 25, 2024
Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.
GENERICally Speaking Hatch Waxman Bulletin
June 10, 2024
Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
GENERICally Speaking Hatch Waxman Bulletin
April 30, 2024
Pharmacyclics LLC v. Alvogen Pine Brook LLC
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.